Core Illumina revenue of $1.04 billion for Q1 2025, down 1% from Q1 2024 (flat on a constant currency basis) GAAP operating margin...
Agilent Technologies Inc. (NYSE: A), a global leader in analytical instrumentation and laboratory solutions, today announced the official inauguration of...
GeneFab, a next-generation cell and gene therapy-focused contract research, development, and manufacturing organization (CRDMO), has partnered with RegCe...
600-patient study to assess efficacy of rhu-pGSN, an immune system regulator that interrupts the NLRP3 inflammasome and boosts macrophage clearance of pa...
Global CDMO supports South Korean company on a multiphase project at its Copenhagen and Chiba sites AGC Biologics, your friendly CDMO expert, ...
Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated resu...
Scorpius Holdings, Inc. (OTC: SCPX), a biomanufacturing company dedicated to advancing therapeutic production capabilities, today announced a comprehensi...
Chengdu Origen Biotechnology Co., Ltd. (“Chengdu Origen”) and Vanotech Ltd. (“Vanotech”) announced the first patient dosed ...
InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced that its new generation...
- Recorded Q1’25 consolidated revenue of KRW 1.3 trillion - Recorded Q1’25 consolidated operating profit of KRW 486.7 billion - Company exp...
Biocon Biologics Ltd (BBL), a fully integrated global biosimilars company and subsidiary of Biocon Ltd announced a settlement and license agreement...
Partnership with specialist life science distributor establishes sales channel in high-demand market and strengthens global network Hypothermic pres...
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild de...
As Asia accounts for nearly half of the world’s cancer burden, the push toward precision medicine is more critical than ever. In this...
© 2025 Biopharma Boardroom. All Rights Reserved.
